PneumRx

Mountain View, United States Founded: 2004 • Age: 22 yrs Acquired By BTG International
Minimally invasive emphysema treatments using Nitinol lung coils are developed.

About PneumRx

PneumRx is a Healthcare company based in Mountain View (United States) founded in 2004, and was acquired by BTG International in December 2014. Minimally invasive emphysema treatments using Nitinol lung coils are developed. PneumRx has raised $49.6 million across 3 funding rounds from investors including SVB, BTG International and Forbion. The company has 7 employees. Its focus areas include Life Sciences, Pulmonology, Medical Devices and Therapeutic Devices. Its legal entity is PNEUMRX INC. Its competitors include Pulmonx, Spiration and Uptake Medical; 3 of its 3 listed competitors have raised funding.

Company details

PneumRx, Inc., a start-up medical device company, develops minimally invasive treatments for emphysema patients. The company develops RePneu Lung Volume Reduction Coil, an investigational device for treating emphysema patients. PneumRx Coils are small, shape-memory Nitinol implants, designed to gather and compress diseased tissue, re-tension the diseased airway network and mechanically increase the elastic recoil in the emphysematous lung. The shape-memory Nitinol Coils are delivered straight into sub-segmental airways through a therapeutic bronchoscope and recover their double-loop shape upon deployment. Part of the BTG group.

  • Headquarters Mountain View, United States
  • Employees 7
  • Stage Acquired
  • Sectors
    Healthcare
  • Website pneumrx.com
  • Social LinkedIn
  • Acquired by BTG International (Dec 2014)
  • Legal Name Pneumrx Inc
Operational Areas
Key Metrics
  • Total Equity Funding
    $49.6M (USD)

    in 3 rounds

  • Latest Funding Round
    $11.88M (USD), Series C

    Dec 2010

  • Investors
    SVB

    & 10 more

  • Employee Count
    7
  • Acquired by

Funding Insights of PneumRx

PneumRx has successfully raised a total of $49.6M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $11.88 million completed in December 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $49.6M
  • Total Rounds 3
  • Last Round Series C β€” $11.88M
  • First Round $10.73M

    (Jun 2005)

  • Investors Count 10

All 3 funding rounds of PneumRx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Dec 2010$11.88MSeries C–Forbion, Endeavour Vision
Mar 2007$27MSeries B–Adams Street Partners, Telegraph Hill Partners
Jun 2005$10.73MSeries A––
–
Valuation history

11 investors in total: 11 institutional.

Investors in PneumRx

PneumRx has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include SVB, BTG International and Forbion.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Venture capital firm focused on lifescience and healthcare sectors
forbion.comNaarden, Netherlands
Endeavour Vision is focused on transformative healthcare technology investments.
endeavourvision.comGeneva, Switzerland
Private markets investment management with strategies in equity, credit, and secondary investments.
adamsstreetpartners.com
Venture capital firm focused on life science, medical device and healthcare companies
thpartners.netSan Francisco, United States
Venture capital firm focused on healthcare companies
altapartners.comJackson, United States
spraypartners.com
Venture debt and equity financing is offered to US startups.
leaderventures.comPalo Alto, United States
sagevp.com
Limited information is provided about KBL Healthcare Ventures.
kblhealthcare.com
Banking services are provided to innovative companies, investors, and individuals.
1983svb.comSanta Clara, United States
Premium access

Investor details for PneumRx

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of PneumRx

4 dated milestones of PneumRx across 10 years, from founding to its latest funding, stage changes and deals.

  1. Founded PneumRx is founded.
  2. Funding First funding round of $10.7M.
  3. Funding Latest funding round, Series C, of $11.9M.
  4. Exit Acquired by BTG International.

Competitors of PneumRx

PneumRx has 3 listed competitors in our database, 3 of them funded. They include Pulmonx, Spiration and Uptake Medical.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
pulmonx.com1998Redwood, United States$280.91M198
Developer of smart devices for treating pulmonary diseases
spiration.com1999Redmond, United States$73.9M74
IntraBronchial Valve to treat lung disease
uptakemedical.com2005Tustin, United States$71.68M
Targeted vapor therapy is developed for endoscopic lung volume reduction.
Premium access

Detailed competitors of PneumRx

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Pulmonology

3 companies that operate in the same segment as PneumRx (Pulmonology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of novel protein-based therapeutics using machine learning and biological engineering
2018Somerville, Massachusetts, United StatesUSD 693 M329
Portable oxygen concentrators are supplied for respiratory therapy needs.
2001Goleta, California, United StatesUSD 51.65 MUSD 348.67 M766
Robotic microsurgical systems for endoscopy are developed.
2007Redwood City, California, United StatesUSD 733.62 M91
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Pneumrx

Premium access

Complete news archive for PneumRx

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about PneumRx

PneumRx was founded in 2004 and raised its 1st funding round 1 year after it was founded.

PneumRx is headquartered in Mountain View, United States. It is registered at Mountain View, California, United States.

PneumRx is a funded company, having raised a total of $49.6M across 3 funding rounds to date. The company's 1st funding round was a Series A of $10.73M, raised on Jun 2005.

PneumRx has 7 employees.

PneumRx, Inc., a start-up medical device company, develops minimally invasive treatments for emphysema patients. The company develops RePneu Lung Volume Reduction Coil, an investigational device for treating emphysema patients. PneumRx Coils are small, shape-memory Nitinol implants, designed to gather and compress diseased tissue, re-tension the diseased airway network and mechanically increase the elastic recoil in the emphysematous lung. The shape-memory Nitinol Coils are delivered straight into sub-segmental airways through a therapeutic bronchoscope and recover their double-loop shape upon deployment. Part of the BTG group.

PneumRx's top competitors include Pulmonx, Spiration and Uptake Medical.

PneumRx has 11 investors. Key investors include SVB, BTG International, Forbion, Endeavour Vision, and Adams Street Partners.

PneumRx operates through Pneumrx Inc.

Yes. PneumRx was acquired by BTG International in December 2014.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available